Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Best Large-Cap & Mid-Cap Pharma Stocks To Buy Now: Daljeet Kohli



Daljeet Kohli of IndiaNivesh has released a detailed report setting out the best pharma stocks to buy now




Daljeet Kohli

In the report, Daljeet Kohli has conducted a detailed analysis of the performance of the top large-cap and mid-cap pharma stocks. He has also estimated the potential earnings of these companies. Thereafter, he has given clear-cut recommendations on what stocks investors should buy, hold and sell

Click here to download the research report on best pharma stocks
Large Cap, Mid Cap, Multibagger, Portfolio, stock picker, Top Picks    , ,

No Comments Yet

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 495 other subscribers

RSS Stocks Talk Forum

  • Sunil Singhania & Madhu Kela are bullish about Himatsingka Seide
    Sunil Singhania & Madhu Kela are bullish about Himatsingka Seide. Singhania's Abakkus Fund holds 6.78% worth ₹137 Cr. Kela's Cohesion MK Fund holds 4.07% worth ₹82 Cr. M-Cap is ₹2100 Cr. Promoters hold 37%. Co is dominant in branded Home Textile with a 'fibre to shelf' model
  • Suraj Estate Developers has a robust project lineup & launch pipeline. TP ₹992 (+73%)
    Suraj Estate Developers has a robust project lineup & launch pipeline, leadership position in redevelopment projects, strong cost advantage, proven track record, huge addressable market and healthy Balance Sheet with predictable cash flows. TP ₹992 (+73%) Download research report... Suraj Estate Developers has a robust project lineup & launch pipeline. TP ₹992 (+73%)
  • DCX Systems has the ability to become a key player in EMS space. TP ₹466 (+54%)
    DCX Systems has the ability to become a key player in EMS space with huge potential in railway & defence. It has ability to deliver high value complicated & critical products for leading defense players L&T & Lockheed. Order book ₹3000 Cr. TP ₹466 (+54%) Download... DCX Systems has the ability to become a key […]
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!